MG0020
MG0020
An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis
Brief summary
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
Medical Condition
Generalized Myasthenia Gravis
Min. Age
18
Years
Max. Age
-
Who Can Join?
All
Status
Active, not recruiting
Inclusion criteria
- Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG) - Study participant is willing to perform and capable of performing home self-administration - Study participant is considered by the investigator for additional rozanolixizumab treatment with the posology proposed in this study. - Body weight ≥35 kg - Study participants may be male or female
Exclusion criteria
- Study participant has a known hypersensitivity to other anti-Fc receptor (FcRn) medications, to any components of the study medication, to any of the excipients (including polysorbate 80), or has a known history of hyperprolinemia, since both polysorbate 80 and L-proline are constituents of the rozanolixizumab formulation - Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current or history of nontuberculous mycobacterial infection (NTMBI) - Study participant has a clinically relevant active infection or a history of serious infection (resulting in hospitalization or requiring IV antibiotic treatment) within 6 weeks before the Baseline Visit - The study participant previously participated in any rozanolixizumab MG study and met any mandatory withdrawal criteria (unless the reason is directly related to MG0020 participation) or mandatory study drug discontinuation criteria. - Study participant has received a live vaccination within 4 weeks before starting treatment, or a Bacillus Calmette–Guérin (BCG) vaccine within 1 year before starting treatment; or intends to have a live vaccination during the course of the study or within 8 weeks following the last dose of rozanolixizumab - Study participant with severe (defined as Grade 3 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis
Study Medication Description
Study Medication:
RYSTIGGO
Other Descriptive Name:
rozanolixizumab
Placebo
No
Comparator:
No
Refer to a friend
Study Dates
April 2023
Actual Start Date of Enrollment
April 2024
Planned Study Completion Date
General Information
Study ID:
MG0020
EudraCT Number:
2022-003870-21
CT.gov Number:
NCT05681715
Phase:
Phase 3